title: Treatment of hepatoma with liposome-encapsulated adriamycin administered into hepatic artery of rats.
abstract: OBJECTIVE
  To observe the therapeutic effects of liposome-encapsulated adriamycin (LADM) on hepatoma in comparison with adriamycin solution (FADM) and adriamycin plus blank liposome (ADM + BL) administered into the hepatic artery of rats.
  
  
  METHODS
  LADM was prepared by pH gradient-driven method. Normal saline, FADM (2 mg/kg), ADM+BL (2 mg/kg), and LADM (2 mg/kg) were injected via the hepatic artery in rats bearing liver W256 carcinosarcoma, which were divided into four groups randomly. The therapeutic effects were evaluated in terms of survival time, tumor enlargement ratio, and tumor necrosis degree. The difference was determined with ANOVA and Dunnett test and log rank test.
  
  
  RESULTS
  Compared to FADM or ADM + BL, LADM produced a more significant tumor inhibition (tumor volume ratio: 1.243 +/- 0.523 vs 1.883 +/- 0.708, 1.847 +/- 0.661, P < 0.01), and more extensive tumor necrosis. The increased life span was prolonged significantly in rats receiving LADM compared with FADM or ADM+BL (231.48 vs 74.66, 94.70) (P < 0.05).
  
  
  CONCLUSIONS
  The anticancer efficacies of adriamycin on hepatoma can be strongly improved by liposomal encapsulation through hepatic arterial administration.
authors.affiliation: Department of Hepatobiliary Surgery, Second Affiliated Hospital, Harbin Medical University, Harbin 150086, Heilongjiang Province, China. sundongsheng_1972@126.com
authors.forename: Dong-Sheng
authors.initials: DS
authors.lastname: Sun
authors.forename: Jiang-Hao
authors.initials: JH
authors.lastname: Chen
authors.forename: Rui
authors.initials: R
authors.lastname: Ling
authors.forename: Qing
authors.initials: Q
authors.lastname: Yao
authors.forename: Ling
authors.initials: L
authors.lastname: Wang
authors.forename: Zhong
authors.initials: Z
authors.lastname: Ma
authors.forename: Yu
authors.initials: Y
authors.lastname: Li
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D006499:Hepatic Artery; D007269:Injections, Intra-Arterial; D008081:Liposomes; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009336:Necrosis / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000903:Antibiotics, Antineoplastic; D008081:Liposomes; D004317:Doxorubicin